Public Sector Pension Investment Board Acquires 19,523 Shares of Omnicell, Inc. $OMCL

Public Sector Pension Investment Board increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,181 shares of the company’s stock after purchasing an additional 19,523 shares during the period. Public Sector Pension Investment Board owned approximately 0.39% of Omnicell worth $5,456,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Omnicell in the second quarter valued at approximately $26,000. First Horizon Corp acquired a new stake in shares of Omnicell during the third quarter worth $31,000. Farther Finance Advisors LLC lifted its position in Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after acquiring an additional 1,036 shares in the last quarter. LSV Asset Management acquired a new position in Omnicell in the 3rd quarter worth $97,000. Finally, Tower Research Capital LLC TRC increased its holdings in Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after purchasing an additional 3,932 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. The trade was a 6.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.52% of the stock is owned by insiders.

Omnicell Trading Up 0.1%

NASDAQ OMCL opened at $38.63 on Friday. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.00. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $45.57 and a 200-day moving average of $37.51. The company has a market cap of $1.73 billion, a PE ratio of 965.99, a PEG ratio of 1.42 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OMCL. Wells Fargo & Company boosted their price target on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Zacks Research lowered Omnicell from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research report on Wednesday, January 7th. Piper Sandler reiterated an “overweight” rating and issued a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Finally, Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.